Dextech Medical (Germany) Top Insiders
| LQ0 Stock | 0.92 0.03 3.37% |
Dextech Medical employs about 1 people. The company is managed by 3 executives with a total tenure of roughly 3 years, averaging almost 1.0 years of service per executive, having 0.33 employees per reported executive. For Dextech Medical AB, management analysis can help investors test whether leadership decisions are reinforcing the broader investment thesis or creating new operating risk. The practical question is whether leadership is creating repeatable business progress instead of simply managing the narrative around the company.
| Anders MD CEO CEO, Founder |
Dextech |
Management Team Effectiveness
The company has return on total asset (ROA) of -14.84 % which implies that asset efficiency is currently in negative territory. This is substantially below the peer group. Similarly, it shows a return on equity (ROE) of -22.81 %, which indicates that stockholders experienced a net loss on invested capital.As of March 2026, Common Stock Shares Outstanding is projected to decline to approximately 14.8 M.
Outstanding Bonds
Corporate bonds issued by Dextech Medical AB matter because they shape interest expense, maturity risk, and the flexibility management has during tighter credit conditions. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Holders Distribution
For Dextech Medical AB, institutional participation can be supportive or destabilizing depending on whether large holders are building conviction or reducing exposure. The better interpretation comes from watching concentration, turnover, and changes in holder behavior instead of assuming institutional ownership is automatically bullish.
Workforce Comparison
Dextech Medical AB holds the top spot in number of employees across its competitive set. The total workforce of Biotechnology industry is now estimated at about 45,335. Dextech Medical adds roughly 1.0 in number of employees claiming only tiny portion of market share in Biotechnology space.
The company has Profit Margin (PM) of -1.84 %, which indicates that revenue growth has not kept pace with cost inflation. This is substantially below the peer group. Benchmark Summation
Operator |
This analysis covers sixty-one data points across the selected time horizon. Dextech Medical AB Price Series Summation is a cross summation of Dextech Medical price series and its benchmark/peer.
Notable Stakeholders
A Dextech Medical stakeholder is any individual or group with an interest in the outcome of the business, which is why stakeholder analysis can reveal who may influence strategy and oversight. The stronger interpretation comes from connecting stakeholder presence with management behavior, governance patterns, and changes in the operating story.
Management Information & Data Sources
Dextech Medical is a micro-cap company in Biotechnology, Healthcare, Drugs. Executive review focuses on insiders, senior management, and employee signals. Changes in insider ownership can offer context, but they should be read with fundamentals and market conditions. CEO is Anders MD with 1 employees and 3 reported executives.
For Dextech Medical AB, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Intraday timing differences may exist. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Manpower analysis for Dextech Medical AB matters because revenue per employee and profit per employee can reveal shifts in productivity and operating discipline. The business is commonly classified in the Healthcare sector and the Biotechnology industry.
Dextech Medical Manpower Efficiency
Return on Dextech Medical Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4.8M | |
| Net Loss Per Executive | 1.6M | |
| Working Capital Per Employee | 14.8M | |
| Working Capital Per Executive | 4.9M |
Popular Tools for Dextech Stock analysis
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |